loading page

Impact of pharmacist-led medication therapy management in ambulatory elderly patients with chronic diseases
  • +4
  • Xin WANG,
  • Shihui Wang,
  • Xiaojia Yu,
  • Zhuo Ma,
  • Huaguang Wang,
  • Jing Yang,
  • Lihong Liu

Corresponding Author:[email protected]

Author Profile
Shihui Wang
Author Profile
Xiaojia Yu
Author Profile
Huaguang Wang
Author Profile
Lihong Liu
Author Profile


Aims: This study aimed to assess the impact of pharmacist-led medication therapy management (MTM) for ambulatory elderly patients with chronic diseases. Methods: Consecutive patients were enrolled from pharmacist outpatient clinics from January 2016 to June 2018. Eligible subjects were performed with MTM services by the pharmacists and had clinical data for at least 2 clinic visits within a consecutive 12-month period after the first MTM visit. The drug-related problems (DRPs) and recommendations were evaluated using The Pharmaceutical Care Network Europe (PCNE) Classification for Drug related problems V8.03. Results: A total of 525 DRPs were identified during the study period. Treatment effectiveness P1 (53.71%) was the most common problems of DRPs. The most frequently recommended intervention was changing the drug (48.76%). These interventions were accepted by the patients in 92.38% and were completely implemented in 90.48%. The number of drugs taken was the significant associated factor for DRPs. Post-intervention group showed lower levels in systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to the pre-intervention group. There were statistically significant changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) between the pre- and post-intervention group. The average cost of medications per patient for every month decreased from 387.72 Ren Min Bi (RMB) to 355.17 RMB (P=0.009). Conclusion: We confirmed that pharmacists has a valuable role to perform MTM services for ambulatory elderly patients, not only in identifying and solving the DRPs, but also in improving clinical outcomes (BP and lipid level) and cost saving.
21 Apr 2020Submitted to British Journal of Clinical Pharmacology
22 Apr 2020Submission Checks Completed
22 Apr 2020Assigned to Editor
28 Apr 2020Reviewer(s) Assigned
25 May 2020Review(s) Completed, Editorial Evaluation Pending
26 May 2020Editorial Decision: Revise Minor
08 Jul 20201st Revision Received
14 Jul 2020Submission Checks Completed
14 Jul 2020Assigned to Editor
14 Jul 2020Review(s) Completed, Editorial Evaluation Pending
15 Jul 2020Reviewer(s) Assigned
03 Aug 2020Editorial Decision: Revise Major
10 Sep 20202nd Revision Received
11 Sep 2020Assigned to Editor
11 Sep 2020Submission Checks Completed
11 Sep 2020Review(s) Completed, Editorial Evaluation Pending
11 Sep 2020Reviewer(s) Assigned
24 Sep 2020Editorial Decision: Revise Minor
13 Oct 20203rd Revision Received
14 Oct 2020Assigned to Editor
14 Oct 2020Submission Checks Completed
14 Oct 2020Review(s) Completed, Editorial Evaluation Pending
15 Oct 2020Reviewer(s) Assigned
06 Nov 2020Editorial Decision: Revise Minor
04 Dec 20204th Revision Received
07 Dec 2020Submission Checks Completed
07 Dec 2020Assigned to Editor
07 Dec 2020Review(s) Completed, Editorial Evaluation Pending
11 Dec 2020Editorial Decision: Accept